- DKK82.80bn
- DKK62.73bn
- DKK21.53bn
- 81
- 53
- 63
- 77
Annual income statement for Genmab A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10,111 | 8,417 | 14,505 | 16,474 | 21,526 |
| Cost of Revenue | |||||
| Gross Profit | — | 8,417 | 14,505 | 16,248 | 20,541 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3,798 | 5,464 | 8,238 | 11,153 | 14,823 |
| Operating Profit | 6,313 | 2,953 | 6,267 | 5,321 | 6,703 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 5,904 | 3,918 | 6,945 | 5,637 | 9,164 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4,758 | 2,957 | 5,452 | 4,352 | 7,844 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 4,758 | 2,957 | 5,452 | 4,352 | 7,844 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 4,758 | 2,957 | 5,452 | 4,352 | 7,844 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 72.5 | 44.8 | 83 | 66 | 126 |
| Dividends per Share |